CONMED Corporation(CNMD)Earnings, Financials & Key Ratios

CNMD•NYSE

$37.32

$1.15B mkt cap·24.7× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustrySurgical tools, endoscopy, and robotics

AboutCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.Show more

Revenue$1.37B+5.2%
EBITDA$193M-28.9%
Net Income$47M-64.5%
EPS (Diluted)1.51-64.6%
Gross Margin52.77%-5.9%
EBITDA Margin14.08%-32.4%
Operating Margin10.27%-33.0%
Net Margin3.42%-66.2%
ROE4.72%-68.0%
ROIC5.77%-30.0%
Debt/Equity0.81-14.1%
Interest Coverage4.54-15.5%

Technical→

CNMD Key Insights

CONMED Corporation (CNMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 37.7%
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.1%
✓Trading at only 1.1x book value

✗Weaknesses

✗Weak momentum: RS Rating 19 (bottom 19%)
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CNMD Price & Volume

CONMED Corporation (CNMD) stock price & volume — 10-year historical chart

Loading chart...

CNMD Growth Metrics

CONMED Corporation (CNMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years6.69%

5 Years9.77%

3 Years9.55%

TTM4.41%

Profit CAGR

10 Years4.43%

5 Years37.66%

3 Years-

TTM-53.81%

EPS CAGR

10 Years3.31%

5 Years36.38%

3 Years-

TTM-53.37%

Return on Capital

10 Years5.57%

5 Years6.79%

3 Years7.67%

Last Year6.99%

CNMD Recent Earnings

CONMED Corporation (CNMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

Apr 29, 2026

EPS

$0.89

Est $0.82

+8.5%

Revenue

$317M

Est $311M

+2.1%

Q1 2026

Jan 28, 2026

EPS

$1.43

Est $1.32

+8.3%

Revenue

$373M

Est $367M

+1.7%

Q4 2025

Nov 5, 2025

EPS

$1.08

Est $1.05

+2.9%

Revenue

$338M

Est $367M

-7.9%

Q3 2025

Jul 30, 2025

EPS

$1.15

Est $1.13

+1.8%

Revenue

$342M

Est $335M

+2.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 29, 2026	$0.89vs $0.82+8.5%	$317Mvs $311M+2.1%
Q1 2026	Jan 28, 2026	$1.43vs $1.32+8.3%	$373Mvs $367M+1.7%
Q4 2025	Nov 5, 2025	$1.08vs $1.05+2.9%	$338Mvs $367M-7.9%
Q3 2025	Jul 30, 2025	$1.15vs $1.13+1.8%	$342Mvs $335M+2.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
HOLXHologic, Inc.Direct Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	0.52
ATRCAtriCure, Inc.Direct Competitor	1.42B	28.01	-116.71	14.88%	-0.83%	-0.95%	0.18
NVCRNovoCure LimitedDirect Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
MMSIMerit Medical Systems, Inc.Direct Competitor	3.68B	61.63	28.93	11.66%	9.03%	8.95%	0.57
LMATLeMaitre Vascular, Inc.Direct Competitor	2.51B	110.22	43.74	13.53%	24.35%	16.19%	0.47
SYKStryker CorporationProduct Competitor	111.96B	292.33	34.80	11.16%	12.92%	15.04%	0.66
ZBHZimmer Biomet Holdings, Inc.Product Competitor	16.22B	82.83	23.33	7.2%	9.05%	5.77%	0.59
BSXBoston Scientific CorporationProduct Competitor	83.23B	56.00	28.87	19.87%	14.4%	12.4%	0.51

Compare CNMD vs Peers

CONMED Corporation (CNMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HOLX

Most directly comparable listed peer for CNMD.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare CNMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs HOLX, ATRC, NVCR, MMSI

CNMD Income Statement

CONMED Corporation (CNMD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	796.39M	859.63M	955.1M	862.46M	1.01B	1.05B	1.24B	1.31B	1.37B	1.37B
Revenue Growth %	4.31%	7.94%	11.11%	-9.7%	17.18%	3.45%	19.06%	5%	5.16%	4.41%
Cost of Goods Sold	365.35M	390.52M	430.38M	402.16M	442.6M	474.23M	568.5M	573.98M	649.12M	636.88M
COGS % of Revenue	45.88%	45.43%	45.06%	46.63%	43.79%	45.36%	45.67%	43.92%	47.23%	-
Gross Profit	431.04M▲ 0%	469.11M▲ 8.8%	524.72M▲ 11.9%	460.3M▼ 12.3%	568.04M▲ 23.4%	571.25M▲ 0.6%	676.25M▲ 18.4%	733.03M▲ 8.4%	725.38M▼ 1.0%	735.25M▲ 0%
Gross Margin %	54.12%	54.57%	54.94%	53.37%	56.21%	54.64%	54.33%	56.08%	52.77%	53.58%
Gross Profit Growth %	5.56%	8.83%	11.85%	-12.28%	23.41%	0.56%	18.38%	8.4%	-1.04%	-
Operating Expenses	384.11M	397.81M	445.6M	414.29M	458.32M	501.19M	555.64M	532.71M	584.24M	581.85M
OpEx % of Revenue	48.23%	46.28%	46.66%	48.04%	45.35%	47.94%	44.64%	40.76%	42.51%	-
Selling, General & Admin	351.8M	355.62M	400.14M	373.82M	414.75M	454.04M	503.04M	478.28M	528.36M	522.43M
SG&A % of Revenue	44.17%	41.37%	41.9%	43.34%	41.04%	43.43%	40.41%	36.59%	38.44%	-
Research & Development	32.31M	42.19M	45.46M	40.47M	43.56M	47.15M	52.6M	54.43M	55.88M	59.27M
R&D % of Revenue	4.06%	4.91%	4.76%	4.69%	4.31%	4.51%	4.23%	4.16%	4.07%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	148K
Operating Income	46.94M▲ 0%	71.31M▲ 51.9%	79.11M▲ 11.0%	46.01M▼ 41.8%	109.72M▲ 138.5%	70.05M▼ 36.2%	120.6M▲ 72.2%	200.33M▲ 66.1%	141.13M▼ 29.5%	155.42M▲ 0%
Operating Margin %	5.89%	8.29%	8.28%	5.33%	10.86%	6.7%	9.69%	15.33%	10.27%	11.33%
Operating Income Growth %	24.58%	51.92%	10.95%	-41.84%	138.46%	-36.15%	72.16%	66.1%	-29.55%	-
EBITDA	105.48M	133.11M	151.44M	118.64M	180.46M	119.81M	192.48M	272.18M	193.47M	219.35M
EBITDA Margin %	13.25%	15.48%	15.86%	13.76%	17.86%	11.46%	15.46%	20.82%	14.08%	15.99%
EBITDA Growth %	13.44%	26.19%	13.77%	-21.66%	52.11%	-33.61%	60.65%	41.41%	-28.92%	-9.94%
D&A (Non-Cash Add-back)	58.55M	61.8M	72.32M	72.63M	70.74M	49.76M	71.87M	71.86M	52.34M	63.93M
EBIT	46.94M	71.31M	73.93M	45.66M	108.59M	-41.96M	120.6M	200.33M	141.13M	155.42M
Net Interest Income	-18.2M	-20.65M	-42.7M	-44.05M	-35.48M	-28.91M	-39.77M	-37.3M	-31.09M	-29.86M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	18.2M	20.65M	42.7M	44.05M	35.48M	28.91M	39.77M	37.3M	31.09M	29.86M
Other Income/Expense	-18.2M	-20.65M	-47.89M	-44.41M	-36.61M	-140.92M	-39.77M	-37.3M	-70.01M	-73.62M
Pretax Income	28.73M▲ 0%	50.65M▲ 76.3%	31.23M▼ 38.4%	1.6M▼ 94.9%	73.11M▲ 4460.5%	-70.86M▼ 196.9%	80.83M▲ 214.1%	163.03M▲ 101.7%	71.12M▼ 56.4%	81.8M▲ 0%
Pretax Margin %	3.61%	5.89%	3.27%	0.19%	7.23%	-6.78%	6.49%	12.47%	5.17%	5.96%
Income Tax	-26.75M	9.8M	2.6M	-7.91M	10.56M	9.72M	16.37M	30.61M	24.06M	26.95M
Effective Tax Rate %	-93.12%	19.35%	8.34%	-493.7%	14.45%	-13.72%	20.25%	18.77%	33.83%	32.95%
Net Income	55.49M▲ 0%	40.85M▼ 26.4%	28.62M▼ 29.9%	9.52M▼ 66.7%	62.54M▲ 557.2%	-80.58M▼ 228.8%	64.46M▲ 180.0%	132.42M▲ 105.4%	47.05M▼ 64.5%	54.85M▲ 0%
Net Margin %	6.97%	4.75%	3%	1.1%	6.19%	-7.71%	5.18%	10.13%	3.42%	4%
Net Income Growth %	278.39%	-26.37%	-29.95%	-66.75%	557.16%	-228.84%	179.99%	105.44%	-64.47%	-53.81%
Net Income (Continuing)	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M	47.05M	54.85M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.97▲ 0%	1.41▼ 28.4%	0.97▼ 31.2%	0.32▼ 67.0%	1.94▲ 506.2%	-2.68▼ 238.1%	2.04▲ 176.1%	4.26▲ 108.8%	1.51▼ 64.6%	1.79▲ 0%
EPS Growth %	278.85%	-28.43%	-31.21%	-67.01%	506.25%	-238.14%	176.12%	108.82%	-64.55%	-53.37%
EPS (Basic)	1.99	1.45	1.01	0.33	2.14	-2.68	2.10	4.29	1.52	-
Diluted Shares Outstanding	28.17M	28.89M	29.5M	29.46M	32.22M	30.04M	31.55M	31.11M	31.15M	30.62M
Basic Shares Outstanding	27.94M	28.12M	28.32M	28.58M	29.16M	30.04M	30.67M	30.85M	31.04M	30.59M
Dividend Payout Ratio	40.2%	54.93%	78.97%	239.76%	37.18%	-	38.01%	18.62%	52.59%	-

CNMD Balance Sheet

CONMED Corporation (CNMD) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	356.78M	374.35M	397.36M	416.65M	460.12M	581.23M	615.65M	640.01M	672.86M	670.59M
Cash & Short-Term Investments	32.62M	17.51M	25.86M	27.36M	20.85M	28.94M	24.3M	24.46M	40.82M	35.03M
Cash Only	32.62M	17.51M	25.86M	27.36M	20.85M	28.94M	24.3M	24.46M	40.82M	35.03M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	167.04M	181.55M	189.1M	177.15M	183.88M	191.34M	242.28M	237.73M	247.83M	0
Days Sales Outstanding	76.56	77.09	72.27	74.97	66.41	66.8	71.04	66.39	65.81	47.01
Inventory	141.44M	154.6M	164.62M	194.87M	231.64M	332.32M	318.32M	346.72M	355.54M	0
Days Inventory Outstanding	141.3	144.49	139.61	176.86	191.03	255.78	204.38	220.48	199.92	104.11
Other Current Assets	0	5.39M	0	0	0	28.62M	30.75M	31.1M	28.67M	635.56M
Total Non-Current Assets	1B	994.79M	1.38B	1.34B	1.31B	1.72B	1.68B	1.67B	1.65B	1.64B
Property, Plant & Equipment	116.23M	113.25M	118.88M	111.41M	108.86M	115.61M	120.72M	115.79M	113.33M	0
Fixed Asset Turnover	6.85x	7.59x	8.03x	7.74x	9.28x	9.04x	10.31x	11.29x	12.13x	23.98x
Goodwill	401.95M	400.44M	618.04M	618.44M	617.53M	815.43M	806.84M	805.36M	807.01M	806.86M
Intangible Assets	414.94M	413.19M	532.8M	501.54M	471.05M	681.8M	649.48M	617.66M	582.05M	573.8M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	63.33M	62.75M	102.35M	96.79M	98.8M	93.88M	96.11M	116.36M	137.19M	820.86M
Total Assets	1.36B▲ 0%	1.37B▲ 0.8%	1.78B▲ 29.7%	1.75B▼ 1.3%	1.77B▲ 0.8%	2.3B▲ 30.1%	2.3B▲ 0.1%	2.31B▲ 0.3%	2.33B▲ 0.8%	2.31B▲ 0%
Asset Turnover	0.59x	0.63x	0.54x	0.49x	0.57x	0.46x	0.54x	0.57x	0.59x	0.59x
Asset Growth %	2.18%	0.82%	29.65%	-1.32%	0.82%	30.1%	0.11%	0.27%	0.85%	3.76%
Total Current Liabilities	150M	160.94M	188.09M	190.2M	196.65M	296.55M	310.73M	278.13M	315.04M	292.72M
Accounts Payable	42.04M	53.5M	55.97M	53.31M	58.2M	73.39M	88.22M	102.25M	93.65M	0
Days Payables Outstanding	42	50	47.47	48.38	47.99	56.49	56.64	65.02	52.66	43.24
Short-Term Debt	14.7M	18.34M	13.25M	18.41M	12.25M	69.75M	0	715K	712K	711K
Deferred Revenue (Current)	34.26M	42.92M	0	0	0	0	0	0	0	0
Other Current Liabilities	59M	46.19M	111.25M	110.81M	126.2M	153.41M	144.22M	175.17M	220.68M	292M
Current Ratio	2.38x	2.33x	2.11x	2.19x	2.34x	1.96x	1.98x	2.30x	2.14x	2.14x
Quick Ratio	1.44x	1.37x	1.24x	1.17x	1.16x	0.84x	0.96x	1.05x	1.01x	1.01x
Cash Conversion Cycle	175.85	171.58	164.41	203.45	209.45	266.09	218.78	221.85	213.08	107.88
Total Non-Current Liabilities	576.53M	545.92M	876.54M	852.43M	783.94M	1.26B	1.16B	1.07B	977.61M	1B
Long-Term Debt	471.74M	438.56M	754.72M	735.22M	672.41M	985.08M	971.48M	905.07M	834.23M	860.16M
Capital Lease Obligations	0	0	17.59M	15.15M	0	0	11.55M	0	0	0
Deferred Tax Liabilities	77.67M	81.06M	74.49M	57.88M	68.54M	66.72M	60.9M	74.08M	79.53M	305.58M
Other Non-Current Liabilities	27.11M	26.3M	29.75M	44.19M	42.99M	203.69M	111.13M	86.29M	63.85M	278.35M
Total Liabilities	726.53M	706.87M	1.06B	1.04B	980.58M	1.55B	1.47B	1.34B	1.29B	1.3B
Total Debt	486.44M	456.9M	793.17M	776.45M	684.66M	1.05B	991.25M	905.78M	834.94M	860.87M
Net Debt	453.82M	439.39M	767.32M	749.09M	663.81M	1.03B	966.96M	881.32M	794.13M	825.84M
Debt / Equity	0.77x	0.69x	1.12x	1.10x	0.87x	1.41x	1.19x	0.94x	0.81x	0.81x
Debt / EBITDA	4.61x	3.43x	5.24x	6.54x	3.79x	8.80x	5.15x	3.33x	4.32x	3.92x
Net Debt / EBITDA	4.30x	3.30x	5.07x	6.31x	3.68x	8.56x	5.02x	3.24x	4.10x	4.10x
Interest Coverage	2.58x	3.45x	1.73x	1.04x	3.06x	-1.45x	3.03x	5.37x	4.54x	5.20x
Total Equity	631.43M▲ 0%	662.27M▲ 4.9%	710.47M▲ 7.3%	709.04M▼ 0.2%	785.43M▲ 10.8%	745.54M▼ 5.1%	834.22M▲ 11.9%	962.68M▲ 15.4%	1.03B▲ 7.3%	1.02B▲ 0%
Equity Growth %	8.76%	4.88%	7.28%	-0.2%	10.77%	-5.08%	11.89%	15.4%	7.31%	33.21%
Book Value per Share	22.41	22.92	24.09	24.06	24.38	24.82	26.44	30.94	33.17	33.23
Total Shareholders' Equity	631.43M	662.27M	710.47M	709.04M	785.43M	745.54M	834.22M	962.68M	1.03B	1.02B
Common Stock	313K	313K	313K	313K	313K	313K	313K	313K	313K	313K
Retained Earnings	440.08M	464.85M	470.84M	457.42M	496.61M	412.63M	452.53M	560.28M	588.77M	602.59M
Treasury Stock	-93.68M	-88.89M	-80.74M	-67.64M	-54.05M	-22.78M	-14.99M	-15.63M	-12.89M	0
Accumulated OCI	-49.08M	-55.74M	-59.28M	-63.68M	-54.2M	-57.86M	-50.17M	-58.86M	-46.3M	-44.69M
Minority Interest	0	0	0	0	0	0	0	0	0	0

CNMD Cash Flow Statement

CONMED Corporation (CNMD) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	65.57M	74.7M	95.13M	64.53M	111.77M	33.37M	125.35M	166.97M	170.69M	170.69M
Operating CF Margin %	8.23%	8.69%	9.96%	7.48%	11.06%	3.19%	10.07%	12.77%	12.42%	-
Operating CF Growth %	71.54%	13.93%	27.35%	-32.17%	73.2%	-70.15%	275.69%	33.2%	2.23%	-88.52%
Net Income	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M	47.05M	54.85M
Depreciation & Amortization	58.55M	61.8M	72.32M	72.63M	70.74M	69.52M	51.4M	51.3M	74.28M	60.2M
Stock-Based Compensation	8.47M	10.04M	11.78M	13.11M	16.34M	21.73M	24.26M	25.56M	28.32M	19.96M
Deferred Taxes	-40.02M	2.06M	-6.31M	-14.23M	3M	-6.04M	700K	12.2M	3.52M	7.72M
Other Non-Cash Items	143.41M	4.21M	12.37M	13.41M	14.84M	119.44M	24.11M	-14.8M	28.96M	11.99M
Working Capital Changes	-16.92M	-44.27M	-23.65M	-29.9M	-55.7M	-90.7M	-39.58M	-39.72M	-11.45M	-12.09M
Change in Receivables	-13.63M	-17.46M	-13.94M	13.92M	-9.16M	-5.2M	-47.07M	-1.62M	-2.36M	-2.74M
Change in Inventory	-3.93M	-15.04M	-117K	-30.4M	-37.81M	-78.56M	14.07M	-31.63M	-6.73M	-11.53M
Change in Payables	-286K	12.11M	38K	-2.98M	4.89M	13.3M	14.85M	14.71M	-9.75M	8.05M
Cash from Investing	-29.05M	-16.51M	-387.66M	-13.64M	-14.87M	-249.53M	-20.03M	-13.08M	-20.96M	-13.92M
Capital Expenditures	-12.84M	-16.51M	-20.07M	-13.01M	-14.87M	-21.79M	-19.03M	-13.08M	-19.81M	-18.92M
CapEx % of Revenue	1.61%	1.92%	2.1%	1.51%	1.47%	2.08%	1.53%	1%	1.44%	-
Acquisitions	-16.21M	0	-367.6M	-3.85M	0	-227.74M	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	3.23M	0	0	-1M	0	-1.15M	5M
Cash from Financing	-34.88M	-72.27M	300.88M	-52.06M	-101.55M	225M	-110.43M	-151M	-135.82M	-129.97M
Debt Issued (Net)	-12.2M	-29.7M	362.85M	-29.4M	-81.24M	362.02M	-88M	-72M	-74.59M	-60M
Equity Issued (Net)	0	0	0	0	0	0	0	0	0	-37.02M
Dividends Paid	-22.31M	-22.44M	-22.6M	-22.82M	-23.26M	-23.96M	-24.5M	-24.65M	-24.75M	-18.57M
Share Repurchases	0	0	-30.57M	0	0	-72M	0	0	0	-37.02M
Other Financing	-372K	-20.12M	-39.37M	162K	2.95M	-113.06M	2.07M	-54.35M	-36.49M	-14.39M
Net Change in Cash	5.19M▲ 0%	-15.11M▼ 390.9%	8.35M▲ 155.2%	1.5M▼ 82.0%	-6.51M▼ 533.9%	8.1M▲ 224.4%	-4.65M▼ 157.4%	163K▲ 103.5%	16.36M▲ 9935.6%	-455K▲ 0%
Free Cash Flow	52.72M▲ 0%	58.19M▲ 10.4%	75.07M▲ 29.0%	51.52M▼ 31.4%	96.9M▲ 88.1%	11.58M▼ 88.1%	106.32M▲ 818.1%	153.88M▲ 44.7%	150.88M▼ 2.0%	123.71M▲ 0%
FCF Margin %	6.62%	6.77%	7.86%	5.97%	9.59%	1.11%	8.54%	11.77%	10.98%	9.02%
FCF Growth %	124.65%	10.37%	28.99%	-31.37%	88.1%	-88.05%	818.1%	44.74%	-1.95%	-24.82%
FCF per Share	1.87	2.01	2.55	1.75	3.01	0.39	3.37	4.95	4.84	4.84
FCF Conversion (FCF/Net Income)	1.18x	1.83x	3.32x	6.78x	1.79x	-0.41x	1.94x	1.26x	3.63x	2.26x
Interest Paid	16.16M	19.66M	27.27M	30.45M	21.8M	26.08M	33.69M	32.65M	25.42M	0
Taxes Paid	8.87M	11.05M	10.58M	9.12M	8.56M	9.07M	19.88M	15.22M	0	0

CNMD Key Ratios

CONMED Corporation (CNMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	9.16%	6.32%	4.17%	1.34%	8.37%	-10.53%	8.16%	14.74%	4.72%	5.4%
Return on Invested Capital (ROIC)	3.31%	4.89%	4.6%	2.35%	5.66%	3.26%	5.06%	8.24%	5.77%	5.77%
Gross Margin	54.12%	54.57%	54.94%	53.37%	56.21%	54.64%	54.33%	56.08%	52.77%	53.58%
Net Margin	6.97%	4.75%	3%	1.1%	6.19%	-7.71%	5.18%	10.13%	3.42%	4%
Debt / Equity	0.77x	0.69x	1.12x	1.10x	0.87x	1.41x	1.19x	0.94x	0.81x	0.81x
Interest Coverage	2.58x	3.45x	1.73x	1.04x	3.06x	-1.45x	3.03x	5.37x	4.54x	5.20x
FCF Conversion	1.18x	1.83x	3.32x	6.78x	1.79x	-0.41x	1.94x	1.26x	3.63x	2.26x
Revenue Growth	4.31%	7.94%	11.11%	-9.7%	17.18%	3.45%	19.06%	5%	5.16%	4.41%

CNMD SEC Filings & Documents

CONMED Corporation (CNMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 29, 2026·SEC

Material company update

Mar 13, 2026·SEC

Material company update

Jan 28, 2026·SEC

10-K Annual Reports

FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Jul 31, 2025·SEC

CNMD Frequently Asked Questions

CONMED Corporation (CNMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

CONMED Corporation (CNMD) reported $1.37B in revenue for fiscal year 2025. This represents a 992% increase from $125.6M in 1996.

CONMED Corporation (CNMD) grew revenue by 5.2% over the past year. This is steady growth.

Yes, CONMED Corporation (CNMD) is profitable, generating $54.8M in net income for fiscal year 2025 (3.4% net margin).

Dividend & Returns

Yes, CONMED Corporation (CNMD) pays a dividend with a yield of 2.13%. This makes it attractive for income-focused investors.

CONMED Corporation (CNMD) has a return on equity (ROE) of 4.7%. This is below average, suggesting room for improvement.

CONMED Corporation (CNMD) generated $123.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CNMD

CONMED Corporation (CNMD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

CONMED Corporation(CNMD)Earnings, Financials & Key Ratios

CNMD Key Insights

✓Strengths

✗Weaknesses

CNMD Price & Volume

CNMD Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CNMD Recent Earnings

CNMD Peer Comparison

Compare CNMD vs Peers

vs HOLX

vs JNJ

Compare Top 5

CNMD Income Statement

CNMD Balance Sheet

CNMD Cash Flow Statement

CNMD Key Ratios

CNMD SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

CNMD Frequently Asked Questions

Explore More CNMD

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation